Exaggerated plasma interleukin 6, interleukin 10, and subsequent development of health care-associated infections in patients with sepsis

Dimensions of Critical Care Nursing

Volumn 34, Issue 2, 2015, Pages 100-111

  Umberger, Reba ^a,b   Thompson, Carol L ^c   Cashion, Ann K ^d   Kuhl, David ^e   Wan, Jim ^f   Yates, Charles R ^f   Muthiah, Muthiah P ^b,f   Meduri, Gianfranco Umberto ^b,f  

^a and Fellow Transcultural Nursing Society Scholars   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY COLLEGE OF NURSING   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e UNION UNIVERSITY   (United States)

^f The University of Tennessee Extension   (United States)

Author keywords

Cytokines; Immunosuppression; Infections; Inflammation; Sepsis

Indexed keywords

IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 10; INTERLEUKIN 6;

AGED; BLOOD; CANDIDEMIA; CROSS INFECTION; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; PROSPECTIVE STUDY; SEPSIS; UNITED STATES;

AGED; CANDIDEMIA; CROSS INFECTION; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; PROSPECTIVE STUDIES; SEPSIS; UNITED STATES;

EID: 84923052923     PISSN: 07304625     EISSN: 15388646     Source Type: Journal    
DOI: 10.1097/DCC.0000000000000098     Document Type: Article

References (44)

1. st century. Clin Infect Dis. 2007;45(suppl 1): S85-S88.
2. Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther. 2012;10(6):701-706.
3. Carson WF, Cavassani KA, Dou Y, Kunkel SL. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics. 2011;6(3):273-283.
4. Kovach MA, Standiford TJ. The function of neutrophils in sepsis. Curr Opin Infect Dis. 2012;25(3):321-327.
5. McCall CE, Yoza BK. Gene silencing in severe systemic inflammation. Am J Respir Crit Care Med. 2007;175(8):763-767.
6. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature. 2005;437(7061):1032-1037.
7. Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host innate immune responses to sepsis. Virulence. 2014;4(8):36-34.
8. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets - an updated view. Mediators Inflamm. 2013:1-16.
9. Kindt TJ, Goldsby RA, Osborne BA. Kuby Immunology. 6th ed. New York: W. H. Freeman and Company; 2007.
10. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260-268.
11. Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167(15):1655-1663.
12. Yende S, D'Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177(11):1242-1247.
13. Delano MJ, Thayer T, Gabrilovich S, et al. Sepsis induces early alterations in innate immunity that impactmortality to secondary infection. J Immunol. 2011;186(1):195-202.
14. Kanangat S, Bronze MS, Meduri GU, et al. Enhanced extracellular growth of Staphylococcus aureus in the presence of selected linear peptide fragments of human interleukin (IL)-1beta and IL-1 receptor antagonist. J Infect Dis. 2001;183(1):65-69.
15. Kanangat S, Meduri GU, Tolley EA, et al. Effects of cytokines and endotoxin on the intracellular growth of bacteria. Infect Immun. 1999;67(6):2834-2840.
16. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res. 2012;160(4):258-266.
17. Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann N Y Acad Sci. 1998;851:311-335.
18. Darville T, O'Neill JM, Andrews CW Jr, Nagarajan UM, Stahl L, Ojcius DM. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol. 2003;171(11):6187-6197.
19. Stephan F, Yang K, Tankovic J, et al. Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med. 2002;30(2):315-322.
20. Kobayashi KS, Flavell RA. Shielding the double-edged sword: negative regulation of the innate immune system. J Leukoc Biol. 2004;75(3):428-433.
21. Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology - The Immune System in Health and Disease. 6th ed. New York, NY: Garland Science Publishing; 2005.
22. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 1999;27(7):1262-1264.
23. McCall CE, Yoza B, Liu T, El Gazzar M. Gene-specific epigenetic regulation in serious infections with systemic inflammation. J Innate Immun. 2010;2(5):395-405.
24. Hall MW, Knatz NL, Vetterly C, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37(3):525-532.
25. Simonatto M, Natoli G. Functional genomics of the inflammatory response: where are we now? Brief Funct Genomics. 2013;12:483-488.
26. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kappaB- and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation. 2005;12(6):321-338.
27. Hoover L, Bochicchio GV, Napolitano LM, et al. Systemic inflammatory response syndrome and nosocomial infection in trauma. J Trauma. 2006;61(2):310-317.
28. Ramírez P, Ferrer M, Gimeno R, et al. Systemic inflammatory response and increased risk for ventilator-associated pneumonia: a preliminary study. Crit Care Med. 2009;37(5):1691-1695.
29. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864-874.
30. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
31. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study.Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-1800.
32. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309-332.
33. Fartoukh M, Maitre B, Honore S, Cerf C, Zahar JR, Brun-Buisson C. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med. 2003;168(2):173-179.
34. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe.Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274(8):639-644.
35. Klevay MJ, Ernst EJ, Hollanbaugh JL, Miller JG, Pfaller MA, Diekema DJ. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis. 2008;60(3):273-277.
36. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care. 2008;12(1):204-212.
37. O'Grady NP, Barie PS, Bartlett JG, et al. Practice guidelines for evaluating new fever in critically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America. Clin Infect Dis. 1998;26(5):1042-1059.
38. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954-963.
39. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76(12):2520-2526.
40. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med. 2002;165(7):983-991.
41. Marshall JC. The PIRO (predisposition, insult, response, organ dysfunction) model: toward a staging system for acute illness. Virulence. 2014;5(1):27-35.
42. Kleinpell R, Aitken L, Schorr CA. Implications of the new international sepsis guidelines for nursing care. Am J Crit Care. 2013;22(3):212-222.
43. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
44. Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. Clin Infect Dis. 2010;51(suppl 1):S131-S135.